ANE MURUETA-GOYENA LARRAÑAGA-rekin lankidetzan egindako argitalpenak (27)

2024

  1. Association of retinal neurodegeneration with the progression of cognitive decline in Parkinson’s disease

    npj Parkinson's Disease, Vol. 10, Núm. 1

  2. Prognostic factors for falls in Parkinson’s disease: a systematic review

    Acta Neurologica Belgica, Vol. 124, Núm. 2, pp. 395-406

2023

  1. Brain Degeneration in Synucleinopathies Based on Analysis of Cognition and Other Nonmotor Features: A Multimodal Imaging Study

    Biomedicines, Vol. 11, Núm. 2

  2. Clinical phenotype of postural orthostatic tachycardia associated with anti-adrenergic receptor antibodies

    Gaceta médica de Bilbao: Revista oficial de la Academia de Ciencias Médicas de Bilbao. Información para profesionales sanitarios, Vol. 120, Núm. 2, pp. 66-73

  3. Correction to: Multimodal visual system analysis as a biomarker of visual hallucinations in Parkinson’s disease (Journal of Neurology, (2023), 270, 1, (519-529), 10.1007/s00415-022-11427-x)

    Journal of Neurology

  4. Diagnostic classification of Parkinson’s disease based on non-motor manifestations and machine learning strategies

    Neural Computing and Applications, Vol. 35, Núm. 8, pp. 5603-5617

  5. Dysautonomia and small fiber neuropathy in post-COVID condition and Chronic Fatigue Syndrome

    Journal of Translational Medicine, Vol. 21, Núm. 1

  6. Multiple system atrophy: Clinical, evolutive and histopathological characteristics of a series of cases

    Neurologia, Vol. 38, Núm. 9, pp. 609-616

  7. Retinal thickness as a biomarker of cognitive impairment in manifest Huntington’s disease

    Journal of Neurology, Vol. 270, Núm. 8, pp. 3821-3829

2022

  1. Brain fog of post-COVID-19 condition and Chronic Fatigue Syndrome, same medical disorder?

    Journal of Translational Medicine, Vol. 20, Núm. 1

  2. Characterization of molecular biomarkers in cerebrospinal fluid and serum of E46K-SNCA mutation carriers

    Parkinsonism and Related Disorders, Vol. 96, pp. 29-35

  3. Impact of Visual Impairment on Vision-Related Quality of Life in Parkinson's Disease

    Journal of Parkinson's Disease, Vol. 12, Núm. 5, pp. 1633-1643

  4. Multimodal visual system analysis as a biomarker of visual hallucinations in Parkinson’s disease

    Journal of Neurology

  5. Plasma and serum alpha-synuclein as a biomarker in Parkinson's disease: A meta-analysis

    Parkinsonism and Related Disorders, Vol. 99, pp. 107-115

  6. Potential Tear Biomarkers for the Diagnosis of Parkinson’s Disease—A Pilot Study

    Proteomes, Vol. 10, Núm. 1

  7. Spatial characterization of the effect of age and sex on macular layer thicknesses and foveal pit morphology

    PLoS ONE, Vol. 17, Núm. 12 December

2021

  1. Clinical long-term nocturnal sleeping disturbances and excessive daytime sleepiness in Parkinson's disease

    PLoS ONE, Vol. 16, Núm. 12 December

  2. Foveal Remodeling of Retinal Microvasculature in Parkinson’s Disease

    Frontiers in Neuroscience, Vol. 15

  3. Foveal pit morphology characterization: A quantitative analysis of the key methodological steps

    Entropy, Vol. 23, Núm. 6

  4. Quantitative analysis of dysautonomia in patients with autonomic dysreflexia

    Journal of Neurology, Vol. 268, Núm. 8, pp. 2985-2994